Pfizer: MHRA (UK) approves Hympavzi (marstacimab) to treat haemophilia A or B in adult and paediatric patients.- Pfizer

The drug has been authorised to prevent or reduce bleeding episodes in patients ages 12 years and older who weigh at least 35kg and have severe haemophilia A without factor VIII inhibitors or severe haemophilia B without factor IX inhibitors. More than 11,800 people were living with haemophilia A or B in the UK in 2023/2024, including 2,700 with severe disease. The genetic blood disorders primarily affect males and are caused by a clotting factor deficiency.